C4 Therapeutics
CCCCClinical Pipeline
Program / Asset
Target Indications
Development Phase
Financial Statements & Analysis
Total Gross Revenue
$6.46M $11.23M $35.95M $6.15M
Cost of Revenue / Sales
— — — —
Gross Profit
— — — —
OPERATING EXPENSES
2025-06-302025-09-302025-12-312026-03-31
Research & Development (R&D)
($26.20M) ($25.99M) ($104.24M) ($24.61M)
Selling & Marketing Expense
— — — —
General & Administrative (G&A)
($8.77M) ($8.92M) ($36.20M) ($9.33M)
Operating Income / (Loss)
($28.50M) ($34.41M) ($115.22M) ($27.79M)
NON-OPERATING & FINANCING ITEMS
2025-06-302025-09-302025-12-312026-03-31
Interest Income / Cash Yields
— — — —
Interest & Debt Servicing Expense
— — — —
Other Non-Operating Income / (Expense)
$2.48M $2.25M $10.35M $2.66M
Income Tax Provision / (Benefit)
$0.00M $0.00M $0.12M $0.00M
NET INCOME / (NET LOSS)
($26.02M) ($32.17M) ($104.99M) ($25.13M)
ASSETS (CURRENT & FIXED)
2025-06-302025-09-302025-12-312026-03-31
Cash and Cash Equivalents
$78.2M$58.8M$74.6M$61.3M
Short-Term Marketable Investments
// --// --// --// --
Total Liquid Cash Resources
$78.2M$58.8M$74.6M$61.3M
Accounts Receivable, Net
$2.2M$6.5M$2.4M$2.9M
Prepaid Expenses & Other Current Assets
$8.0M$8.4M$7.2M$6.8M
Total Current Assets
$224.7M$206.9M$258.1M$245.4M
Property, Plant and Equipment, Net
$5.5M$5.1M$4.7M$4.5M
Intangibles & Other Non-Current Assets
// --// --// --// --
TOTAL CONSOLIDATED ASSETS
$296.5M$265.5M$359.1M$328.9M
LIABILITIES & STOCKHOLDERS' EQUITY
2025-06-302025-09-302025-12-312026-03-31
Accounts Payable
$2.2M$1.3M$0.9M$0.8M
Accrued Expenses & Clinical Liabilities
// --// --// --// --
Total Current Liabilities
$44.5M$35.9M$33.0M$27.2M
Long-Term Corporate Debt Balances
// --// --// --// --
Deferred Revenue & Collaboration Liabilities
// --// --// --// --
Other Long-Term Obligations
$78.0M$75.1M$69.5M$67.4M
Total Liabilities Block
$122.5M$111.1M$102.5M$94.6M
Total Stockholders' Equity
$174.1M$154.4M$256.6M$234.2M
TOTAL LIABILITIES & EQUITY
$296.5M$265.5M$359.1M$328.9M
HISTORICAL RATIO ANALYSIS
2025-06-302025-09-302025-12-312026-03-31
Current Liquidity Ratio
5.06x 5.76x 7.81x 9.00x
R&D Expenditure Flow
$53.3M$79.3M$104.2M$24.6M
Net Income / (Loss)
($26.02M) ($32.17M) ($104.99M) ($25.13M)
Depreciation & Amortization
$1.07M $1.53M $1.96M $0.40M
Stock-Based Compensation
$10.50M $15.09M $19.10M $2.67M
Change in Accounts Receivable
($0.90M) $3.44M ($0.70M) $0.48M
Change in Prepaid Assets / Expenses
($3.97M) ($3.40M) ($1.14M) ($0.12M)
Change in Payables & Clinical Accruals
$0.89M $0.00M ($0.47M) ($0.09M)
Other Operating Source / (Use) Changes
($26.91M) ($61.05M) ($12.45M) ($8.16M)
Net Cash from Operating Activities
($45.34M) ($76.55M) ($98.69M) ($29.94M)
INVESTING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Capital Expenditures (CapEx)
($0.18M) ($0.60M) ($0.61M) ($0.06M)
Purchases of Marketable Securities
($47.32M) ($94.00M) ($227.07M) ($40.81M)
Maturities & Sales of Investments
$115.55M $166.73M $219.08M $57.03M
Net Cash from Investing Activities
$68.05M $72.13M ($8.60M) $16.15M
FINANCING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Proceeds from Issuing Debt Instruments
— — — —
Repayments of Debt / Leases
— — — —
Proceeds from Issuing Stock / ATM Options
— — — —
Net Cash from Financing Activities
($0.05M) $7.73M $126.40M $0.46M
NET CONSOLIDATED CHANGE IN CASH
$22.66M $3.31M $19.10M ($13.33M)